Curis, Inc. (NASDAQ:CRIS) Short Interest Update

Curis, Inc. (NASDAQ:CRIS) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 137,000 shares, an increase of 26.6% from the October 15th total of 108,200 shares. Based on an average daily volume of 55,800 shares, the days-to-cover ratio is presently 2.5 days. Currently, 1.8% of the company’s stock are short sold.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. increased its position in shares of Curis by 795.5% during the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after acquiring an additional 96,256 shares during the period. CM Management LLC increased its position in shares of Curis by 380.0% during the first quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after acquiring an additional 95,000 shares during the period. Focused Wealth Management Inc increased its position in shares of Curis by 63.1% during the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 20,908 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the period. Institutional investors own 29.97% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Curis in a research report on Friday.

Curis Stock Performance

Shares of CRIS traded down $0.03 during mid-day trading on Friday, reaching $3.95. The company had a trading volume of 96,519 shares, compared to its average volume of 40,146. The company has a market capitalization of $23.62 million, a price-to-earnings ratio of -0.49 and a beta of 3.35. Curis has a 52 week low of $3.51 and a 52 week high of $17.49. The firm has a 50-day moving average price of $5.06 and a 200 day moving average price of $7.21.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.